Literature DB >> 8056422

Assessment of the value of immunohistochemistry in the subtyping of acute leukemia on routinely processed bone marrow biopsy specimens with particular reference to macrophage-associated antibodies.

H P Horny1, M Wehrmann, B Steinke, E Kaiserling.   

Abstract

The value of immunohistochemical staining in the subtyping of acute leukemia was investigated on 36 routinely processed (formalin-fixed and paraffin-embedded) trephine biopsy specimens from the iliac crest containing diffuse infiltrates of acute myelogenous leukemia (AML; n = 23) and acute lymphoblastic leukemia (ALL; n = 13). These were stained with a broad panel of antibodies (n = 23) against various leukocyte antigens, among them 11 macrophage-associated antibodies (MAAs): Ki-M1p, MAC387, HAM56, LN5, KP1 (CD68), PG-M1 (CD68), Ki-M4p, DAKO-DRC (CD35), and antibodies against lysozyme, alpha 1-antichymotrypsin, and S100 protein. The French-American-British (FAB) classification subtypes of the AML cases, as determined by enzyme-cytochemical and/or immunocytological investigation of bone marrow smears, were as follows: M1 = 6, M2 = 5, M4 = 7, M5 = 3, and AML (not classified) = 2. The 13 cases of ALL were classified as follows: c-ALL (pre-B-ALL) = 7, B-ALL = 3, T-ALL = 2, and ALL (not classified) = 1. All the MAAs except LN5, Ki-M4p, and DAKO-DRC stained blast cells in AML. However, the number of stained blast cells varied considerably within and between the individual subtypes (M4/5 > M2/1). Using Fisher's exact test a significant difference in frequency of blast cell staining between AML and ALL was found for four MAAs (anti-lysozyme, MAC387, Ki-M1p, and KP1) and two of the three myeloid cell markers applied (Ki-My2p and anti-neutrophil elastase). Of these six antibodies, the combination of anti-lysozyme and KP1 can be recommended for use in routine diagnostics for the differentiation of AML from ALL on the basis of immunohistochemical staining because both of these antibodies were found to stain a relatively large percentage of cases of AML but none of ALL. However, none of the MAAs were found to discriminate reliably between the FAB M4/5 and M1/2 subtypes of AML.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056422     DOI: 10.1016/0046-8177(94)90251-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens.

Authors:  B Toth; M Wehrmann; E Kaiserling; H P Horny
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens.

Authors:  S M Kröber; A Greschniok; E Kaiserling; H P Horny
Journal:  Mol Pathol       Date:  2000-04

3.  The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia.

Authors:  Marwan Qubaja; Béatrice Marmey; Agnès Le Tourneau; Stéphanie Haiat; Dominique Cazals-Hatem; Bettina Fabiani; Jacques Diebold; Jean-Pierre Marie; Josée Audouin; Frédéric Geissmann; Thierry Jo Molina
Journal:  Virchows Arch       Date:  2009-02-26       Impact factor: 4.064

4.  SARS spike protein induces phenotypic conversion of human B cells to macrophage-like cells.

Authors:  Shu-Fen Chiang; Tze-Yi Lin; Kuan-Chih Chow; Shiow-Her Chiou
Journal:  Mol Immunol       Date:  2010-07-27       Impact factor: 4.407

5.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Authors:  Hiba Ahmad Zahreddine; Biljana Culjkovic-Kraljacic; Sarit Assouline; Patrick Gendron; Andrea A Romeo; Stephen J Morris; Gregory Cormack; James B Jaquith; Leandro Cerchietti; Eftihia Cocolakis; Abdellatif Amri; Julie Bergeron; Brian Leber; Michael W Becker; Shanshan Pei; Craig T Jordan; Wilson H Miller; Katherine L B Borden
Journal:  Nature       Date:  2014-05-28       Impact factor: 49.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.